Table 2.
Primary antibodies to extracellular matrix molecules and inflammatory cells
| Molecule | Antibody name/clone | Marker | IF/IHa | Reference/source |
|---|---|---|---|---|
| Mouse | ||||
| Pan-Laminin | 455 | All BMs | IF, IH | [80]b |
| Laminin α2 | 401 | Parenchymal BM | IF | [77]b |
| Laminin α4 | 377 | Endothelial BM | IF | [73]b |
| Laminin α5 | 405 | Endothelial BM | IF | [80]b |
| Collagen IV | – | All BMs | IF | [86]c |
| P-Selectin | Rabbit anti-P-selectin | Activated endothelium | IH | [22], BD Pharmingen |
| ICAM-1 | 25ZC7 | Endothelial adhesion molecule | IF, IH | [72], BD Pharmingen |
| ICAM-2 | 3C4 | Endothelial adhesion molecule | IH | BD Pharmingen |
| VCAM-1 | 9DB3 | Endothelial adhesion molecule | IF, IH | [29], BD Pharmingen |
| PECAM-1 | Mec13.3 | Endothelial junctions | IH | BD Pharmingen |
| Ly6G | 1A8 | PMNs | IF, IH | [17], BD Pharmingen |
| Ly6C | AL-21 | Monocytes | IF | [17], BD Pharmingen |
| Gr-1 | RB6-8C5 | PMNs, monocytes | IF, IH | [35], BD Pharmingen |
| F4/80 | A3-1 | Macrophages | IF, IH | BD Pharmingen |
| CD45 |
30G12 M1-9 |
All leukocytes |
IF IH |
BD Pharmingen |
| CD11b/Mac-1 | M1/70 | Microglia, monocytes, macrophages | IF, IH | BD Pharmingen |
| CD41 | MWreg30 | Platelets | IF, IH | BD Pharmingen |
| IgG | 236 BA-9200 | Murine IgG | IF, IH | BD Pharmingen |
| Antigen | Antibody name/clone | Marker | IF/IHa | Reference/source |
|---|---|---|---|---|
| Human | ||||
| CD3 | Polyclonal | T lymphocytes | IH | Dako |
| CD15 | C3D-1 | PMNs, monocytes | IH, IF | Dako |
| CD45 | 2B11 | All leukocytes | IH, IF | Dako |
| CD68 | PG-M1 | Activated macrophages, monocytes, microglia | IH, IF | Dako |
| LCA | PD7/26 | All leukocytes | IH | Dako |
| Hif1alpha | NB 100-134 | Hypoxia | IH | Novus biologicals |
| c.Caspase-3 | Asp 175 | Apoptotic cells | IH | Cell signaling |
aEmployed in IF immunofluorescence or IH immunohistochemistry
bProvided by L. Sorokin
cKindly provided by K. von der Mark (Erlangen)